There are two large semiconductor companies reporting after the close today (that is, Thursday). One of them is Applied Materials (AMAT). Here is the long-term chart:
Two After the Close
Slope of Hope Blog Posts
Slope initially began as a blog, so this is where most of the website’s content resides. Here we have tens of thousands of posts dating back over a decade. These are listed in reverse chronological order. Click on any category icon below to see posts tagged with that particular subject, or click on a word in the category cloud on the right side of the screen for more specific choices.
A Bad Trip
Here are a couple of travel-related firms that aren’t participating in this most overly-supported equity market in human history. Both of these got zapped hard on Thursday.
House in the House
One sector has been unabashedly (and surprisingly) strong for the entirety of 2019: home-builders. Check these two funds out:
Smoke Gets In Your Eyes
As a follow-up to the Up In Smoke post from a week ago, pot stocks just keep getting destroyed. Here is Tilray, down about 95% from its peak.
Taxi!
It seems these days that anything SoftBank Group touches turns to garbage. WeWork is the most publicized exampled, but their huge example in UBER is just as bad. What’s remarkable is that both UBER and LYFT, breathlessly anticipated before their public offerings, have both been wrecks.
Broker and Broker
This past week, one sector which took it on the chin was the brokerages. The reason is easy enough to understand. Two important revenue sources for them are (1) commissions and (2) interest on deposits. And yet (1) commissions are going to $0 across the board and (2) interest rates are plunging, and ultimately, I believe, will be negative. So here is the kind of catastrophe these companies are facing, with most of them down nearly 50% from their highs last year:
Healthy Momentum
By Harry Boxer, TheTechTrader
Medical stocks dominate today’s top charts to watch.
AbbVie Inc. (ABBV) climbed $1.72 to $73.85 on 6.2 million shares Thursday. The move came on no news from the maker of Humira and other drugs. The stock has been rallying for the last month, breaking out of a 1 1/2-year declining channel. However, it pulled back on Tuesday and Wednesday to test support before Thursday’s bounce. Watch for a move next to recent highs near $76.
(more…)